A share price of Sutro Biopharma Inc [STRO] is currently trading at $1.87, saw in change for the day. An important factor to consider is whether the stock is rising or falling in short-term value. The STRO shares have gain 15.08% over the last week, with a monthly amount drifted -6.97%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on May 08, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $12. Previously, Deutsche Bank started tracking the stock with Buy rating on November 09, 2023, and set its price target to $12. On October 06, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $10 on the stock. Wells Fargo downgraded its rating to a Equal Weight and decreased its price target to $8 on March 21, 2023. H.C. Wainwright started tracking with a Buy rating for this stock on June 18, 2021, and assigned it a price target of $35. In a note dated December 03, 2020, Stifel initiated an Buy rating and provided a target price of $25 on this stock.
Sutro Biopharma Inc experienced fluctuations in its stock price throughout the past year between $1.51 and $6.13. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $1.87 at the most recent close of the market. An investor can expect a potential return of 541.71% based on the average STRO price forecast.
Analyzing the STRO fundamentals
Trailing Twelve Months sales for Sutro Biopharma Inc [NASDAQ:STRO] were 160.96M which represents -49.66% decline. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -0.81%, Pretax Profit Margin comes in at -0.67%, and Net Profit Margin reading is -0.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.97 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8033 points at the first support level, and at 1.7367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9333, and for the 2nd resistance point, it is at 1.9967.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sutro Biopharma Inc [NASDAQ:STRO] is 3.09. On the other hand, the Quick Ratio is 3.09, and the Cash Ratio is 1.33. Considering the valuation of this stock, the price to sales ratio is 0.96, the price to book ratio is 1.39.
